Radiofrequency Ablation and Percutaneous Ethanol Injection Treatment for Recurrent Local and Distant Well-Differentiated Thyroid Carcinoma

Objective:To assess the long-term efficacy of radiofrequency ablation (RFA) and percutaneous ethanol (EtOH) injection treatment of local recurrence or focal distant metastases of well-differentiated thyroid cancer (WTC). Background:RFA and EtOH injection techniques are new minimally invasive surgical alternatives for treatment of recurrent WTC. We report our experience and long-term follow-up results using RFA or EtOH ablation in treating local recurrence and distant focal metastases from WTC. Methods:Twenty patients underwent treatment of biopsy-proven recurrent WTC in the neck. Sixteen of these patients had lesions treated by ultrasound-guided RFA (mean size, 17.0 mm; range, 8–40 mm), while 6 had ultrasound-guided EtOH injection treatment (mean size, 11.4 mm; range, 6–15 mm). Four patients underwent RFA treatment of focal distant metastases from WTC. Three of these patients had CT-guided RFA of bone metastases (mean size, 40.0 mm; range, 30–60 mm), and 1 patient underwent RFA for a solitary lung metastasis (size, 27 mm). Patients were then followed with routine ultrasound, 131I whole body scan, and/or serum thyroglobulin levels for recurrence at the treatment site. Results:No recurrent disease was detected at the treatment site in 14 of the 16 patients treated with RFA and in all 6 patients treated with EtOH injection at a mean follow-up of 40.7 and 18.7 months, respectively. Two of the 3 patients treated for bone metastases are free of disease at the treatment site at 44 and 53 months of follow-up, respectively. The patient who underwent RFA for a solitary lung metastasis is free of disease at the treatment site at 10 months of follow-up. No complications were experienced in the group treated by EtOH injection, while 1 minor skin burn and 1 permanent vocal cord paralysis occurred in the RFA treatment group. Conclusions:RFA and EtOH ablation show promise as alternatives to surgical treatment of recurrent WTC in patients with difficult reoperations. Further long-term follow-up studies are necessary to determine the precise role these therapies should play in the treatment of recurrent WTC.

[1]  I. Sugitani,et al.  A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. , 2004, Surgery.

[2]  Carlo Bartolozzi,et al.  Percutaneous ablation of hepatocellular carcinoma: State‐of‐the‐art , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[3]  M. Ringel,et al.  Clinical review 158: Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. , 2003, The Journal of clinical endocrinology and metabolism.

[4]  F. Pacini.  Role of percutaneous ethanol injection in management of nodular lesions of the thyroid gland. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  A. Oberg,et al.  Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients , 2002, World Journal of Surgery.

[6]  G. Y. Wong,et al.  Painful metastases involving bone: feasibility of percutaneous CT- and US-guided radio-frequency ablation. , 2002, Radiology.

[7]  J. Charboneau,et al.  Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. , 2002, AJR. American journal of roentgenology.

[8]  D. Dupuy,et al.  Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. , 2001, Surgery.

[9]  S. Cascinu,et al.  Novel therapeutic approaches to cancer patients with bone metastasis. , 2001, Critical reviews in oncology/hematology.

[10]  D E Dupuy,et al.  Image-guided radiofrequency tumor ablation: challenges and opportunities--part II. , 2001, Journal of vascular and interventional radiology : JVIR.

[11]  D E Dupuy,et al.  Image-guided radiofrequency tumor ablation: challenges and opportunities--part I. , 2001, Journal of vascular and interventional radiology : JVIR.

[12]  G. Hejblum,et al.  Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. , 2001, The Journal of clinical endocrinology and metabolism.

[13]  T. Petrich,et al.  Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age , 2001, European Journal of Nuclear Medicine.

[14]  G. Gazelle,et al.  Tumor ablation with radio-frequency energy. , 2000, Radiology.

[15]  P R Mueller,et al.  Radio-frequency ablation of renal cell carcinoma: early clinical experience. , 2000, Radiology.

[16]  D E Dupuy,et al.  Radiofrequency ablation of spinal tumors: temperature distribution in the spinal canal. , 2000, AJR. American journal of roentgenology.

[17]  P. Fonseca.  Thyroid lung metastasis diagnosed 47 years after thyroidectomy. , 1999, The Annals of thoracic surgery.

[18]  H J Mankin,et al.  Percutaneous Radiofrequency Coagulation of Osteoid Osteoma Compared with Operative Treatment* , 1998, The Journal of bone and joint surgery. American volume.

[19]  P. Yeo,et al.  Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. , 1997, The Journal of clinical endocrinology and metabolism.

[20]  C. Key,et al.  Prognostic factors for thyroid carcinoma , 1997, Cancer.

[21]  S. Noguchi,et al.  Classification of papillary cancer of the thyroid based on prognosis , 1994, World Journal of Surgery.

[22]  D. Johnston,et al.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. , 1992, The Journal of clinical endocrinology and metabolism.

[23]  P. Fossati,et al.  Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine? , 1992, World Journal of Surgery.

[24]  G. Masarotto,et al.  Distant Metastases in Differentiated Thyroid Cancer: Long-term Results of Radioiodine Treatment and Statistical Analysis of Prognostic Factors in 214 Patients , 1991, Tumori.

[25]  J. Charboneau,et al.  Persistent primary hyperparathyroidism: successful ultrasound-guided percutaneous ethanol ablation of an occult adenoma. , 1988, Mayo Clinic proceedings.

[26]  E. Bergstralh,et al.  Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. , 1988, The Journal of clinical endocrinology and metabolism.

[27]  B. Caillou,et al.  Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. , 1986, The Journal of clinical endocrinology and metabolism.

[28]  N. Niles.  Pathologic Basis of Disease , 1974 .

[29]  D. Dupuy,et al.  Radiofrequency Ablation for Skeletal Metastasis of Papillary Carcinoma of the Thyroid: Conjunct Treatment With Radioablative Iodine , 2004 .

[30]  D. Dupuy,et al.  Radiofrequency Ablation of Recurrent Thyroid Cancer , 2004 .

[31]  W W Mayo-Smith,et al.  Percutaneous radiofrequency ablation of malignancies in the lung. , 2000, AJR. American journal of roentgenology.

[32]  J. Cronan,et al.  Image-Guided Biopsy and Radiofrequency Ablation of Renal Masses , 2000 .

[33]  Taylor Murray,et al.  Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.

[34]  S. Robbins,et al.  Pathologic basis of disease , 1974 .